BR112021016669A2 - Tratamento de herpes simples com uma combinação de valaciclovir e fanciclovir - Google Patents

Tratamento de herpes simples com uma combinação de valaciclovir e fanciclovir

Info

Publication number
BR112021016669A2
BR112021016669A2 BR112021016669A BR112021016669A BR112021016669A2 BR 112021016669 A2 BR112021016669 A2 BR 112021016669A2 BR 112021016669 A BR112021016669 A BR 112021016669A BR 112021016669 A BR112021016669 A BR 112021016669A BR 112021016669 A2 BR112021016669 A2 BR 112021016669A2
Authority
BR
Brazil
Prior art keywords
valacyclovir
famciclovir
treatment
combination
herpes simplex
Prior art date
Application number
BR112021016669A
Other languages
English (en)
Inventor
Christina Ramirez
A Checcone Emidio
Original Assignee
Elian Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elian Llc filed Critical Elian Llc
Publication of BR112021016669A2 publication Critical patent/BR112021016669A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

tratamento de herpes simples com uma combinação de valaciclovir e fanciclovir. a presente divulgação fornece composições e métodos para a prevenção de infecção por hsv em um indivíduo soronegativo para hsv e para o tratamento e a prevenção de recorrência em um indivíduo soropositivo para hsv.
BR112021016669A 2019-02-25 2020-02-25 Tratamento de herpes simples com uma combinação de valaciclovir e fanciclovir BR112021016669A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962810074P 2019-02-25 2019-02-25
PCT/US2020/019700 WO2020176506A1 (en) 2019-02-25 2020-02-25 Treatment of herpes simplex with a combination of valacyclovir and famciclovir

Publications (1)

Publication Number Publication Date
BR112021016669A2 true BR112021016669A2 (pt) 2021-11-09

Family

ID=70228783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016669A BR112021016669A2 (pt) 2019-02-25 2020-02-25 Tratamento de herpes simples com uma combinação de valaciclovir e fanciclovir

Country Status (12)

Country Link
US (2) US11696918B2 (pt)
EP (1) EP3930721A1 (pt)
JP (1) JP2022521651A (pt)
KR (1) KR20210131394A (pt)
CN (1) CN113727715A (pt)
AU (1) AU2020228361A1 (pt)
BR (1) BR112021016669A2 (pt)
CA (1) CA3131159A1 (pt)
IL (1) IL285742A (pt)
MX (1) MX2021010063A (pt)
SG (1) SG11202108881WA (pt)
WO (1) WO2020176506A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071745B2 (en) * 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
WO2022197627A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197626A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2022197625A1 (en) * 2021-03-15 2022-09-22 Drugarray, Inc. Combination therapy for treating covid-19
WO2024097158A1 (en) * 2022-11-01 2024-05-10 Ramirez Christina M Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107303A (en) 1999-03-15 2000-08-22 Demarco; Charlene C. Treatment of Epstein Barr infection
US7253175B2 (en) 2003-11-13 2007-08-07 Barnet Liberman Method for treating athlete's foot
SG11201700061PA (en) * 2014-07-07 2017-02-27 Prophylaxis LLC Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Also Published As

Publication number Publication date
US20230310439A1 (en) 2023-10-05
JP2022521651A (ja) 2022-04-11
US11696918B2 (en) 2023-07-11
AU2020228361A1 (en) 2021-10-07
CA3131159A1 (en) 2020-09-03
EP3930721A1 (en) 2022-01-05
US20200397791A1 (en) 2020-12-24
CN113727715A (zh) 2021-11-30
KR20210131394A (ko) 2021-11-02
WO2020176506A1 (en) 2020-09-03
SG11202108881WA (en) 2021-09-29
MX2021010063A (es) 2021-11-12
IL285742A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
BR112021016669A2 (pt) Tratamento de herpes simples com uma combinação de valaciclovir e fanciclovir
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
GT201700059A (es) Uso de páneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
UY36538A (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
CO2018009096A2 (es) Composiciones que contienen tucaresol o sus análogos
BR112018001874A2 (pt) sistemas e métodos para a modulação fototerápica do óxido nítrico
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
EP4233840A3 (en) Combinations of linagliptin and metformin
BR112017009440A2 (pt) uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112023014751A2 (pt) Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão
EP4342545A3 (en) Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
TW201612054A (en) Head lamp system and straddled vehicle
CO2020015167A2 (es) Variante de antígeno de virus de varicela zóster y uso de la misma
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
BR112016028998A2 (pt) composição polimerizável para material óptico e uso da mesma
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
CO2021007006A2 (es) Moduladores de la expresión de irf5
AR108890A1 (es) Inhibidores de la entrada del cmvh
BR112017015340A2 (pt) uso de taurina na prevenção e/ou tratamento de doenças induzidas por vírus do gênero coronavírus e/ou gênero rotavírus
CL2021002307A1 (es) Uso de virus oncolíticos para el tratamiento del cáncer